- Report
- February 2020
- 40 Pages
Japan
From €2493EUR$2,595USD£2,140GBP
- Report
- February 2020
- 40 Pages
South Korea
From €2493EUR$2,595USD£2,140GBP
- Report
- February 2020
- 40 Pages
India
From €2493EUR$2,595USD£2,140GBP
- Report
- February 2024
- 97 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- June 2023
- 73 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- February 2022
- 102 Pages
Global
From €3200EUR$3,568USD£2,843GBP
- Report
- July 2021
- 92 Pages
Global
From €3200EUR$3,568USD£2,843GBP
- Report
- June 2021
- 87 Pages
Global
From €3200EUR$3,568USD£2,843GBP
- Report
- August 2023
- 74 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- November 2022
- 696 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- May 2022
- 55 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- May 2022
- 68 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- May 2022
- 46 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- May 2022
- 86 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- February 2020
- 40 Pages
United States
From €2493EUR$2,595USD£2,140GBP
- Report
- February 2020
- 40 Pages
Russia
From €2493EUR$2,595USD£2,140GBP
- Report
- February 2020
- 40 Pages
Ireland
From €2493EUR$2,595USD£2,140GBP
- Report
- February 2020
- 40 Pages
Germany
From €2493EUR$2,595USD£2,140GBP
The Multiple Sclerosis (MS) Drug market is a subset of the Central Nervous System (CNS) Drugs market. MS is a chronic, progressive neurological disorder that affects the central nervous system, causing a wide range of physical and mental symptoms. MS drugs are used to reduce the frequency and severity of MS relapses, slow the progression of the disease, and improve the quality of life of those affected.
MS drugs are typically divided into two categories: disease-modifying therapies (DMTs) and symptomatic therapies. DMTs are used to slow the progression of the disease, while symptomatic therapies are used to manage the symptoms of MS. Common DMTs include interferon beta, glatiramer acetate, fingolimod, and natalizumab. Common symptomatic therapies include muscle relaxants, antispasmodics, and antidepressants.
The MS Drug market is highly competitive, with a number of major pharmaceutical companies competing for market share. Some of the major players in the market include Biogen, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more